Search
Now showing items 1-6 of 6
Investment performance of life-science venture capital investment funds, persistence, and subsector analysis
(Massachusetts Institute of Technology, 2007)
Venture capital investment performance data and performance attribution are not typically published. Venture investors articulate (and sell to LPs) conflicting strategies; the popular business literature and culture is ...
Faculty as founder? : an examination of faculty's role in biomedical start-ups
(Massachusetts Institute of Technology, 2005)
Executive Summary: In this thesis, I examine faculty inventors' involvement in university spin-off firms formed to commercialize their inventions. In particular, I analyze the association between a faculty inventor's various ...
Market application of a novel stent-based patency monitor to the management of ischemic vascular disease
(Massachusetts Institute of Technology, 2006)
The use of stents following angioplasty in ischemic arterial beds is limited by complications and continuing vascular deterioration. A phenomenon called stent restenosis post procedure exists which puts patients at a ...
The pharmaco-economics of combination therapies : a study of the effects of component and market factors on combined therapy price
(Massachusetts Institute of Technology, 2006)
For a growing number of indications, combination therapies are becoming increasingly common due in part to their superior efficacy, as compared to monotherapies. In fact, in the case of infectious diseases such as AIDS and ...
Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development
(Massachusetts Institute of Technology, 2006)
I study several aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, ...
An investigation of alliances between western life-science therapeutic and Indian firms
(Massachusetts Institute of Technology, 2008)
Large pharmaceutical companies (Multinational Pharmaceutical Companies or MPCs) have struggled in recent years with the rapidly accelerating costs of drug-discovery research and development. These costs continue to rise ...